The authors describe decreases in wastage and return rates in their Pharmacy Service department in a 471-bed tertiary hospital. Through procedural changes in mixing and delivery schedules, stability updating, and daily communication with the Nursing Service, Pharmacy Service dropped from a 3.9% to a 1.44% wastage rate and from a 15.75% to an 8.2% return rate in a period of 17 months. The specific changes that led to this result are presented for consideration. The primary focus was on determining and noting accountability of involved staff members to decrease returns, missed treatments, and ultimately wastage of costly intravenous admixtures. The 0.9% wastage rate in the seventeenth month suggests that continued efforts may lead to further reductions.
Download full-text PDF |
Source |
---|
Eur J Hosp Pharm
December 2024
Department of Pharmacy Practice, Loma Linda University School of Pharmacy, Loma Linda, California, USA
Objective: Sodium polystyrene sulfonate (SPS) and sodium zirconium cyclosilicate (SZC) have been used for treating acute hyperkalaemia. The pharmacodynamic properties of SZC suggest greater theoretical utility in the acute setting than SPS, but there is no clear guidance on an optimal potassium binder. This study evaluated the efficacy of SZC and SPS in the treatment of acute hyperkalaemia.
View Article and Find Full Text PDFEur J Hosp Pharm
December 2024
JVF Intensive Care Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
Small
January 2025
School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, 646000, China.
Covalent organic frameworks (COFs), known for their exceptional in situ encapsulation and precise release capabilities, are emerging as pioneering drug delivery systems. This study introduces a hypoxia-responsive COF designed to encapsulate the chemotherapy drug gambogic acid (GA) in situ. Bimetallic gold-palladium islands were grown on UiO-66-NH (UiO) to form UiO@Au-Pd (UAPi), which were encapsulated with GA through COF membrane formation, resulting in a core-shell structure (UAPiGC).
View Article and Find Full Text PDFGut
December 2024
Gastroenterology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), Madrid, Spain
Background And Objectives: Primary objectives: to compare the rates of sustained clinical remission at 12 months in patients treated with antitumour necrosis factor (anti-TNF) and immunomodulators who withdraw anti-TNF treatment versus those who maintain it.
Secondary Objectives: to evaluate the effect of anti-TNF withdrawal on relapse-free time, endoscopic and radiological activity, safety, quality of life and work productivity; and to identify predictive factors for relapse.
Design: Prospective, quadruple-blind, multicentre, randomised, controlled trial.
Nat Commun
January 2025
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
We conducted a phase I trial to determine the optimal dose of triplet therapy with the tyrosine kinase inhibitor sitravatinib plus nivolumab plus ipilimumab in 22 previously untreated patients with advanced clear cell renal cell carcinoma. The primary endpoint was safety. Secondary endpoints were objective response rate (ORR), disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), 1-year survival probability, and sitravatinib pharmacokinetics.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!